Here are 14 recent drug shortages and discontinuations, according to FDA drug supply databases:
- Acetaminophen; oxycodone hydrochloride tablet: Multiple strengths of Percocet were discontinued Nov. 3 due to the end of manufacturing.
- Atazanavir sulfate; cobicistat tablet: Evotaz was discontinued Nov. 3. Global manufacturing is expected to cease beginning in April.
- Everolimus tablet: The 2 mg, 3 mg and 5 mg strengths were discontinued Nov. 3.
- Lasmiditan succinate tablet: All 50 mg and 100 mg presentations of Reyvow were discontinued Nov. 3 as a business decision.
- Scopolamine transdermal system: Discontinued Nov. 3.
- Phenobarbital tablet: All strengths — including 16.2 mg, 32.4 mg, 64.8 mg and 97.2 mg — were discontinued Oct. 31.
- Moxifloxacin injection: The 400 mg/250 mL formulation was discontinued Oct. 29.
- Pramlintide acetate injection: SymlinPen 60 and 120 were discontinued Oct. 27.
- Busulfan injection: The 6 mg/mL presentation was discontinued Oct. 24.
- Insulin glargine injection: The Basaglar U-100 Tempo Pen was discontinued Oct. 24.
- Insulin lispro injection: The Humalog U-100 Tempo Pen was discontinued Oct. 24.
- Insulin lispro-aabc injection: The Lyumjev U-100 Tempo Pen and sample were discontinued Oct. 24.
- Lorazepam injection: Currently in shortage due to increased demand.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.